Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, California, USA.
Department of Andrology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
Neurourol Urodyn. 2022 Aug;41(6):1323-1335. doi: 10.1002/nau.24939. Epub 2022 Apr 22.
To determine the outcomes and mechanisms of microenergy acoustic pulse (MAP) therapy in an irreversible rat model of female stress urinary incontinence.
Twenty-four female Sprague-Dawley rats were randomly assigned into four groups: sham control (sham), vaginal balloon dilation and ovariectomy (VBDO), VBDO + β-aminopropionitrile (BAPN), and VBDO + β-aminopropionitrile treated with MAP (MAP). MAP therapy was administered twice per week for 4 weeks. After a 1-week washout period, all 24 rats were evaluated with functional and histological studies. The urethral vascular plexus was examined by immunofluorescence staining with antibodies against collagen IV and von Willebrand factor (vWF). The urethral smooth muscle stem/progenitor cells (uSMPCs) were isolated and functionally studied in vivo and in vitro.
Functional study with leak point pressure (LPP) measurement showed that the MAP group had significantly higher LPPs compared to VBDO and BAPN groups. MAP ameliorated the decline in urethral wall thickness and increased the amount of extracellular matrix within the urethral wall, especially in the urethral and vaginal elastic fibers. MAP also improved the disruption of the urethral vascular plexus in the treated animals. In addition, MAP enhanced the regeneration of urethral and vaginal smooth muscle, and uSMPCs could be induced by MAP to differentiate into smooth muscle and neuron-like cells in vitro.
MAP appears to restore urethral wall integrity by increasing muscle content in the urethra and the vagina and by improving the urethral vascular plexus and the extracellular matrix.
在不可逆的雌性压力性尿失禁大鼠模型中,确定微能量声脉冲 (MAP) 治疗的结果和机制。
将 24 只雌性 Sprague-Dawley 大鼠随机分为 4 组:假手术对照 (sham)、阴道球囊扩张和卵巢切除术 (VBDO)、VBDO+β-氨基丙腈 (BAPN) 和 VBDO+β-氨基丙腈联合 MAP 治疗 (MAP)。MAP 治疗每周进行两次,共 4 周。1 周洗脱期后,所有 24 只大鼠均进行功能和组织学评估。用针对胶原 IV 和血管性血友病因子 (vWF) 的抗体进行免疫荧光染色,检查尿道血管丛。分离尿道平滑肌干细胞/祖细胞 (uSMPCs),并在体内和体外进行功能研究。
漏点压 (LPP) 测量的功能研究表明,MAP 组的 LPP 明显高于 VBDO 和 BAPN 组。MAP 改善了尿道壁厚度的下降,并增加了尿道壁内细胞外基质的量,特别是在尿道和阴道弹性纤维中。MAP 还改善了治疗动物尿道血管丛的破坏。此外,MAP 增强了尿道和阴道平滑肌的再生,MAP 可诱导 uSMPCs 在体外分化为平滑肌和神经元样细胞。
MAP 似乎通过增加尿道和阴道的肌肉含量、改善尿道血管丛和细胞外基质,来恢复尿道壁的完整性。